Pascal Soriot (AP Images)
July 27, 2020 06:14 AM EDTUpdated July 28, 05:02 AM
Deals

As­traZeneca mines an­oth­er $6B ADC from Dai­ichi Sankyo, with block­buster am­bi­tions to ‘re­de­fine treat­ment stan­dards’

Amber Tong

Pas­cal So­ri­ot isn’t let­ting the all-con­sum­ing R&D and man­u­fac­tur­ing work on a Covid-19 vac­cine slow down his hunt for As­traZeneca’s next block­buster can­cer drugs. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times